Design of a Non-Interventional Study to Assess Neurologists' Perspectives and Pharmacological Treatment Decisions in Early Alzheimer's Disease.

Abstract in brief

• The study examines how neurologists are using new anti-amyloid-β disease-modifying therapies (DMTs) for early Alzheimer's disease (AD) and aims to understand their decision-making factors, particularly in the context of uncertainty and risk.
• Conducted as a web-based survey involving 400 neurologists in Spain, the research will gather demographic data and evaluate their responses to simulated patient scenarios related to treatment initiation with DMTs.
• The outcomes will shed light on trends in therapeutic inertia (delays in treatment initiation) and provide insights into the factors that influence neurologists' treatment choices for early AD.